ILMN logo

Illumina Inc. (ILMN)

$202.61

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ILMN

Market cap

$30.63B

EPS

5.81

P/E ratio

51.9

Price to sales

9.35

Dividend yield

--

Beta

1.46574

Price on ILMN

Previous close

$198

Today's open

$199.73

Day's range

$196.61 - $203.11

52 week range

$112.65 - $309.35

Profile about ILMN

CEO

Jacob Thaysen

Employees

8600

Headquarters

San Diego, CA

Exchange

Nasdaq Global Select

Shares outstanding

151200000

Issue type

Common Stock

ILMN industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ILMN

Diamond Hill Mid Cap Strategy Q3 2026 Portfolio Review

The Strategy declined 3.83% (net of fees) and the Russell Midcap Index declined 3.00%. Key contributors include Illumina, Revvity and Waystar. Key detractors include Regal Rexnord, Rocket Companies and Red Rock Resorts.

news source

Seeking Alpha • 16 hours ago

news preview

Illumina Sees Strong Clinical Demand, but Research Recovery Remains in Question

Illumina NASDAQ: ILMN is seeing strong demand for its sequencing instruments from clinical customers, while remaining cautious about a recovery in research spending, Chief Financial Officer Ankur Dhingra said at a company news event.

news source

MarketBeat • Nov 17, 2026

news preview

Illumina, Inc. (ILMN) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Illumina, Inc. (ILMN) Presents at Jefferies Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • Nov 17, 2026

news preview

Thrivent Mid Cap Stock Fund Q3 2026 Performance Review

Thrivent Mid Cap Stock Fund returned (2.92%) versus the Russell Mid Cap Index's (3.00%) return. Top contributors include Veeva Systems, Illumina and Zebra Tech. Top detractors include RH and UL Solutions.

news source

Seeking Alpha • Nov 17, 2026

news preview

Illumina Bets on Clinical Demand for Growth as Research Funding Uncertainty Persists

Illumina NASDAQ: ILMN expects clinical demand and sequencing consumables to remain central to its growth strategy, even as research customers continue to face uncertainty over grant funding, executives said at a UBS discussion.

news source

MarketBeat • Nov 11, 2026

news preview

Illumina, Inc. (ILMN) Presents at 2026 UBS Global Healthcare Conference Transcript

Illumina, Inc. (ILMN) Presents at 2026 UBS Global Healthcare Conference Transcript

news source

Seeking Alpha • Nov 10, 2026

news preview

Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology

Early access program launches to support ultrasensitive research into molecular residual disease and tumor evolution. New chemistry is optimized for highest possible accuracy, with reproducible detection of ctDNA at 2.5 parts per million levels with low sample input (10 nanograms) in representative studies SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced an expansion of its molecular residual disease (MRD) research portfolio with an early access program for an ultrasensitive sequencing workflow.

news source

PRNewsWire • Nov 9, 2026

news preview

REGN vs. ILMN: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Regeneron (REGN) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?

news source

Zacks Investment Research • Nov 4, 2026

news preview

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

SG-INSIGHT study will extend whole-genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be implemented in Singapore's healthcare system SINGAPORE, Nov. 2, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) today announced it has been selected to provide whole-genome sequencing services for the SG-INSIGHT study, a cohort under Phase III of Singapore's National Precision Medicine (NPM) programme. Expected to include approximately one in 10 Singapore residents, or around 450,000 individuals, the study is designed to generate evidence from genomic and health data to help inform preventive approaches to healthcare.

news source

PRNewsWire • Nov 3, 2026

news preview

Don't Overlook Illumina (ILMN) International Revenue Trends While Assessing the Stock

Explore Illumina's (ILMN) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

news source

Zacks Investment Research • Nov 2, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Illumina Inc.

Open an M1 investment account to buy and sell Illumina Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ILMN on M1